Sage Journals: Discover world-class research

Abstract

French

Objective:

Second-generation antipsychotics (SGAs) are used for a variety of mental disorders and are associated with cardiometabolic side effects in children. The objective of this study was to assess the cardiovascular health of children with mental disorders that are SGA-treated or SGA-naive.

Methods:

SGA-treated (n = 47) or SGA-naive (n = 37) children (aged 6 to 18 years) with mental disorders and control children (n = 83, no mental disorder) underwent assessment for cardiac function and morphology by echocardiography, aortic pulse wave velocity (PWV), and carotid intima-media thickness (cIMT). Body mass index (BMI) z-scores, waist circumference z-scores, systolic and diastolic blood pressure (BP) percentiles for height and sex, and fasting plasma glucose, insulin, triglycerides, and cholesterol were also assessed. Differences between SGA-treated, SGA-naive, and control children were assessed by linear and log-linear regression models.

Results:

SGA-treated children had greater BMI z-scores and overweight/obesity (BMI ≥ 85th percentile for age and sex) and hypertension than SGA-naive and control children. The PWV geometric mean was 11.1% higher in SGA-treated (95%CI, 3.95 to 18.77) and 12.9% higher in SGA-naive children (95% CI, 5.60 to 20.59) compared to controls in models adjusted for age, sex, BMI, and systolic BP percentile. Left ventricular (LV) end-diastolic dimension/body surface area (BSA), LV end-systolic dimension/BSA, and LV ejection fraction were lower in SGA-treated and SGA-naive children compared to controls in models adjusted for sex and age.

Conclusions:

Children with mental disorders have greater arterial stiffness and altered cardiac structure/function than children with no mental health diagnosis. SGA treatment in children is not associated with alterations in cardiovascular structure/function.

Keywords

children second-generation antipsychotics arterial stiffness pulse wave velocity carotid intima-media thickness cardiovascular disease

Introduction

In Canada, it is estimated that 14% (1.2 million) of children and youth under the age of 19 years are affected by a mental health disorder.¹ Similarly, 13% to 18% of children (8 to 18 years of age) in the United States are estimated to have a mental health disorder.² It is well-known that adults with mental health disorders, such as bipolar disorder or schizophrenia, have a greater risk of cardiovascular disease and cardiovascular mortality.^3
–5 Given that mental health disorders start in childhood, the cardiovascular damage associated with these conditions may also begin in childhood. This is concerning because the presence of cardiovascular damage, such as greater arterial stiffness or carotid intima-media thickness (cIMT), in childhood is predictive of poor cardiovascular health in adulthood.^6,7 Some indicators of cardiovascular damage have been reported in young adults with major depressive disorder and bipolar disorder prompting a scientific statement from the American Heart Association in 2015.⁸ Further, symptoms of mental illness such as anxiety and depression have also been reported to be associated with indicators of endothelial dysfunction and arterial stiffness.^9

–12

Medication side effects may also contribute to the greater risk of cardiovascular disease in individuals with mental illness. In adults, treatment with second-generation antipsychotics (SGAs) is associated with cardiometabolic complications including rapid weight gain, dyslipidemia, insulin resistance, and hypertension.¹³ Population-based studies have reported associations between risk of cardiovascular disease and SGA treatment in adults with mental illness.⁵ Another study of adults with schizophrenia, mood disorders, or dementia reported greater risk of acute myocardial infarction with short-term SGA treatment.¹⁴

SGAs are increasingly being prescribed to children and adolescents and are often used off-label as an effective treatment of a variety of mental health disorders including attention deficit hyperactivity disorder, anxiety disorder, bipolar disorder, and autism spectrum disorder.^15
–17 We and others have reported similar rapid weight gain, obesity, hypertension, and metabolic dysfunction in SGA-treated children,^{18

–25} and compared to adults, there is evidence that these complications appear faster and to a greater extent in children.^26,27 Recent studies also estimate that SGA-treated children have a 3-fold greater risk of type 2 diabetes compared to untreated children.^28,29

There is a growing concern regarding the long-term health of SGA-treated children because of the metabolic complications. It is well-known that childhood obesity is associated with risk factors such as hypertension and dyslipidemia, but there is also evidence that childhood obesity has direct effects on cardiovascular structure and function.³⁰ Several studies in children have reported positive associations between adiposity and cIMT,^31,32 a subclinical indicator of atherosclerosis³³; greater pulse wave velocity (PWV),³⁴ a measure of arterial stiffness³⁵; and greater left ventricular (LV) mass,³⁶ which may lead to impaired long-term cardiac mechanics and function.³⁷ To date, only 1 study in adults has reported a positive association between SGA treatment and greater PWV compared to untreated subjects.³⁸ The objective of this study was to assess arterial stiffness, cIMT, and cardiac structure and function in SGA-treated children, children with mental illness who were not treated with SGAs (SGA-naive), and control children with no mental illness.

Materials and Methods

Study Design and Subject Recruitment

Children aged 6 to 18 years were recruited between August 1, 2012, and June 1, 2018, from inpatient and outpatient psychiatric units at BC Children’s Hospital in Vancouver, Canada. Written informed consent was obtained from parent(s)/legal guardian(s), and assent was obtained from subjects when capable. Ethics approval for this study was obtained from the University of British Columbia Clinical Research Ethics Board and the Children’s and Women’s Health Centre of British Columbia Research Ethics Board certificate H12-00954. From August 1, 2012, to June 1, 2018, a total of 115 children with a mental health diagnosis were recruited for this study. Of these, 84 children were studied: n = 37 in the SGA-naive group and n = 47 in the SGA-treated group. There were n = 31 children who were not studied due to changes in antipsychotic medication regimen, study noncompliance, and loss to follow-up of scheduling the study visit.

Enrolled subjects were categorized by SGA treatment as follows: SGA-treated, continuous treatment with an SGA for ≥ 3 months and SGA-naive, no current or previous treatment with an SGA. SGA-treated and SGA-naive children were often treated with other psychiatric medications such as antidepressants or psychostimulants. Data from SGA-treated and SGA-naive children were also compared to a group of age- and sex-matched children (n = 83), with no mental illness and no current or previous treatment with psychiatric medications, who underwent standard echocardiography at the BC Children’s Hospital Heart Centre. Data on the control subjects have been published.³⁹ Exclusion criteria for all groups of children included the following: any metabolic disorder (e.g., type 1 or 2 diabetes, polycystic ovary syndrome), any genetic disorder (e.g., Down syndrome, Prader–Willi syndrome), eating disorder, fetal alcohol spectrum disorder, treatment with medications known to affect metabolism (e.g., glucocorticoids, thyroxine, propranolol), and illicit substance use.

Anthropometric, Clinical, and Biochemical Analyses

Medical records were reviewed at the time of recruitment for sociodemographic information (sex and date of birth), medical and family history, medication use (history, dose, and duration), and psychiatric diagnoses as determined by the attending psychiatrist per the multiaxial evaluation system of the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, Text Revision (DSM-IV-TR).⁴⁰ Interviews with participants and families were conducted to obtain information regarding self-reported ethnicity, smoking habits, and self-reported pubertal status according to Tanner staging.^41,42

Anthropometric data were collected by the research assistant. Height was recorded to the nearest 0.1 cm using a Seca 240 Stadiometer (Hamburg, Germany), and weight was recorded to the nearest 0.1 kg using a ScaleTronix 5002 Mobile Stand-On Scale (White Plains, NY). Body mass index (BMI) was calculated (weight [kg]/height² [m²]), and z-scores and percentiles were determined by adjusting for age and sex as per the U.S. Centers for Disease Control and Prevention growth chart data.⁴³ Subjects were categorized into healthy weight (BMI < 85th percentile), overweight (BMI ≥ 85th percentile), or obesity (BMI ≥ 95th percentile). Hip (at maximal protrusion of the gluteus) and waist circumference (at the umbilicus) were measured to the nearest 0.1 cm using an Almedic measuring tape, and the average of 2 readings was recorded. As per the International Diabetes Federation criteria for metabolic syndrome, subjects were categorized by waist circumference as healthy (<90th percentile for age and sex) or elevated (≥90th percentile), and by waist-to-height ratio as healthy (<85th percentile for age and sex) or elevated (≥85th percentile).⁴⁴ Total body fat mass percentage was quantified by bioelectric impedance analysis using the BC-418 Tanita Body Composition Analyzer (Tanita Corporation).

Blood pressure (BP) was measured by a registered nurse as per clinical guidelines⁴⁵. A GE Carescape V100 monitor (GE Medical Systems) was used to measure BP in children who were seated in a chair with feet resting on the floor with the right arm supported at the level of the heart. Systolic BP (SBP) and diastolic BP (DBP) percentiles adjusted for age, sex, and height were used to categorize subjects as normal, elevated, or stage 1 or 2 hypertension according to the 2017 American Academy of Pediatrics Clinical Practice Guidelines for Screening and Management of High Blood Pressure.⁴⁵

A blood sample was collected by venipuncture following an overnight fast. The following biochemical markers were quantified in plasma by the Children’s and Women’s Laboratory at BC Children’s Hospital: fasting glucose, fasting insulin, triglycerides, total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. Insulin resistance was estimated by fasting glucose and insulin concentrations using the homeostatic model assessment-2 of insulin resistance (HOMA2-IR) calculator.⁴⁶

Echocardiography and Vascular Measurements

Standard M-mode, 2-dimensional echocardiography and Doppler imaging were performed by a clinical pediatric echocardiography technician using a Vivid system (GE Vingmed Ultrasound AS) and a 3.5-MHz transducer according to published standards.⁴⁷ Data from LV end-diastolic dimension (LVED) and LV end-systolic dimension (LVES) are expressed per body surface area (BSA), calculated using the Haycock formula.⁴⁸ LV ejection fraction and shortening fraction were quantified from the M-mode tracings. LV mass was calculated using the Devereux formula and was indexed to height (m)^2.7.^49,50

The biophysical properties of the aorta were measured using a previously established echocardiographic Doppler method.^51,52 A pulsed-wave Doppler trace (interval from the Q wave on the echocardiogram to the onset of the Doppler envelope) was obtained from the proximal ascending aorta in a suprasternal long-axis view. The difference between the QRS signal and the onset of flow was time 1. A second pulsed-wave Doppler trace was then obtained in the descending aorta, and the difference between the QRS signal and the onset of flow was used to obtain time 2. Transit time was calculated from the difference between times 2 and 1. The length of the aortic arch between these 2 locations was measured. The following formula was used to calculate aortic PWV: aortic arch length/transit time.

cIMT was determined as previously described.⁵³ Briefly, the far wall of the right and left common carotid arteries, within 2 cm of the carotid bifurcation, were measured using GE EchoPAC software Version 113 (GE Healthcare, Chicago, IL). Measurements were performed over a uniform length of 10 mm (standard deviation of each measurement < 0.1 mm), and an average reading was obtained from a minimum of 3 cIMT measurements from each carotid artery (minimum of 6 measurements total).

Statistical Analyses

Categorical variables were presented as number and percentage and analyzed across groups using Pearson’s χ²-test or Fisher’s exact test as applicable. Continuous variables were presented as mean (standard deviation) or median (25th, 75th percentiles). Student’s t test or Wilcoxon rank sum test was used for comparisons between 2 groups. One-way analysis of variance or Kruskal–Wallis test was used for the comparison between the 3 groups as applicable. Following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines,⁵⁴ hypothesis testing was not conducted to compare the demographic characteristics.

Linear regression models were used to assess the effect of SGA treatment on cIMT, LV ejection fraction, LVED, and LVES. Log-linear regression models were used to assess the effect of SGA treatment on log values of aortic PWV. The estimates from the log-linear models were transformed back and presented as geometric mean difference (%) for more intuitive interpretations. Models were adjusted for covariates selected a priori (age, sex, BMI, SBP percentile, LDL, heart rate). All statistical analyses were conducted in Stata statistical software Version 14.2 (StataCorp, College Station, TX).

Results

Demographic and clinical characteristics of the study population are presented in Table 1. The most common mental health diagnoses in the SGA-treated and SGA-naive groups were anxiety disorder, attention deficit hyperactivity disorder, and autism spectrum disorder. The most common SGA was risperidone (51%) followed by quetiapine (26%) and aripiprazole (23%). The median duration of SGA treatment was 15.0 months (7.3, 28.3 [25th, 75th percentiles]). The majority of the SGA-treated (87%) and SGA-naive (92%) children were taking other medications; the most common were antidepressants followed by psychostimulants. Data on self-reported ethnicity and pubertal status (Tanner stage) were not available from the control subjects. Most subjects were in Tanner stage II or III for pubertal development. The majority of subjects were of European descent. None of the children reported smoking.

Table 1.

Demographic Characteristics of the Study Population.

Subject Characteristics	Children with Mental Illness		Control Children (n = 83)
Subject Characteristics	SGA-treated (n = 47)	SGA-naive (n = 37)	Control Children (n = 83)
Age (years), mean (SD)	12.2 (3.1)	10.9 (2.4)	10.5 (4.2)
Male, n (%)	33 (70)	25 (68)	42 (50.6)
Inpatient, n (%)	21 (46)	29 (76)	0 (0)
Ethnicity, n (%)
European	30 (64)	27 (73)
Non-European	17 (36)	10 (27)
Pubertal status (Tanner), n (%)
I	13 (28)	11 (30)
II and III	16 (34)	20 (54)
IV and V	18 (38)	6 (16)
SGA medication, n (%)
Risperidone	24 (51)	N/A	N/A
Quetiapine	12 (26)
Aripiprazole	11 (23)
SGA duration, median months (25th, 75th)	15.0 (7.3, 28.3)	N/A	N/A
Other medications, n (%)	41 (87)	34 (92)	N/A
Antidepressants	23 (49)	23 (62)
Psychostimulants	10 (21)	5 (14)
Other medications^a	4 (8.5)	4 (11)
Primary diagnosis, n (%)
ADHD	13 (27.7)	7 (18.9)	N/A
Anxiety disorder	10 (21.3)	19 (51.4)
Autism spectrum disorder	6 (12.8)	4 (10.8)
Bipolar disorder	4 (8.5)	1 (2.7)
Schizophrenia/ psychotic disorder	4 (8.5)	0 (0.0)
Other mental disorder^b	10 (21.3)	6 (16.2)

Note. ADHD = attention deficit hyperactivity disorder; SD = standard deviation; SGA = second-generation antipsychotic.

^a Includes mood stabilizers, anxiolytics, atomoxetine, melatonin.

^b Includes depressive disorder, disruptive behavior disorder, learning/communication disorder, neurodevelopmental disorder, oppositional defiant disorder, somatoform disorder, reactive attachment disorder, and mental disorder due to a general medical condition not otherwise specified.

The anthropometric and metabolic characteristics of the study population are summarized in Table 2. SGA-naive and SGA-treated children had higher BMI z-scores and a higher prevalence of overweight/obesity compared to control children. SGA-treated children had greater BMI z-scores, total body fat percentage, waist circumference z-scores, and waist-to-height ratio z-scores than SGA-naive children. No differences in plasma total, LDL, or HDL cholesterol or triglyceride concentrations were observed between SGA-treated and SGA-naive children. SGA-treated children had greater HOMA2-IR and a higher prevalence of elevated fasting plasma insulin concentrations than SGA-naive children (Table 2). More SGA-treated children were categorized as having elevated SBP or DBP (13%) or as having stage 1 or 2 hypertension (15%) compared to SGA-naive children (11% and 5%, respectively) and the control children (11% and 6%, respectively).

Table 2.

Anthropometric and Metabolic Characteristics in Children with Mental Health Conditions and Control Children.

Characteristics	Children with Mental Illness		Control (n = 83)	P value
Characteristics	SGA-treated (n = 47)	SGA-naive (n = 37)	Control (n = 83)	P value
Height z-score	0.163 (1.15)	0.094 (1.21)	0.189 (0.87)	0.899
BMI z-score^a	1.19 (1.08)	0.71 (1.28)	0.25 (0.98)	<0.001
Overweight, n (%)	9 (19.2)	5 (13.9)	8 (9.6)	<0.001
Obesity, n (%)	18 (38.3)	11 (30.6)	9 (10.8)
Total body fat percentage	28.8 (22.6, 37.8)	21.2 (18.5, 26.3)	—	0.002
Waist circumference z-score	1.13 (0.38, 2.01)	0.66 (0.01, 1.33)	—	0.030
≥90th percentile, n (%)	22 (46.8)	10 (28.6)		0.094
Waist-to-height ratio z-score	1.06 (0.28, 1.82)	0.61 (0.11, 1.48)	—	0.029
≥85th percentile, n (%)	24 (51.1)	12 (34.3)		0.130
Body surface area (m²)^b	1.55 (0.45)	1.31 (0.36)	1.24 (0.40)	<0.001
Heart rate (beats/min)	85 (14.9)	80 (12.0)	75.2 (14.0)	0.001
SBP percentile	60 (32, 77)	65 (25, 83)	53 (36, 75)	0.949
DBP percentile	38 (23, 54)	38 (24, 55)	53 (37, 74)	0.001
Elevated SBP or DBP, n (%)	6 (13.0)	4 (10.8)	9 (10.8)	0.429
Stage 1 or 2 hypertension	7 (15.2)	2 (5.4)	5 (6.0)
Fasting glucose (mmol/L)	5.09 (0.31)	4.94 (0.45)	—	0.085
Fasting insulin (pmol/L)	60.0 (32.5, 93.8)	40.0 (27.0, 54.0)	—	0.016
≥100 pmol/L, n (%)	10 (21.7)	4 (12.9)		0.324
HOMA2-IR	1.11 (0.60, 1.77)	0.76 (0.51, 1.02)	—	0.015
Triglycerides (mmol/L)	0.90 (0.65, 1.51)	0.76 (0.55, 1.23)	—	0.201
Total cholesterol (mmol/L)	4.39 (0.97)	4.34 (0.71)	—	0.801
LDL cholesterol (mmol/L)	2.59 (0.86)	2.53 (0.70)	—	0.747
HDL cholesterol (mmol/L)	1.29 (0.31)	1.43 (0.45)	—	0.093

Note. Data are presented as mean (SD) or median (25th, 75th percentiles). Categorical variables are presented as n (%). BMI = body mass index; DBP = diastolic blood pressure; HDL = high-density lipoprotein; HOMA2-IR: homeostatic model assessment-2 of insulin resistance; LDL: low-density lipoprotein; SBP: systolic blood pressure; SGA: second-generation antipsychotic.

^a Overweight, BMI 85th to 94.9th percentile for age and sex; obesity, BMI ≥ 95th percentile for age and sex.

^b Body surface area was calculated using the Haycock formula.⁴⁸

Measures of vascular and cardiac structure and function are presented in Table 3. Aortic PWV was higher in SGA-treated and SGA-naive children compared to control children. After adjusting for age, sex, BMI, and SBP percentile, the geometric mean of aortic PWV was 12.9% higher (95% CI, 5.60 to 20.6; P < 0.001) in the SGA-naive children and 11.1% higher in the SGA-treated children (95% CI, 3.95 to 18.8; P = 0.002) compared to control children (Table 4). No differences in aortic PWV or cIMT were observed between the SGA-treated and SGA-naive subjects in adjusted or unadjusted models.

Table 3.

Cardiovascular Function in Children with Mental Health Conditions and Control Children.

Cardiovascular Parameters	Children with Mental Illness		Control (n = 83)	P Value
Cardiovascular Parameters	SGA-treated (n = 40)	SGA-naive (n = 34)	Control (n = 83)	P Value
Vascular function
PWV (cm/s), median (25th, 75th percentiles)	431.7 (393.7, 483.1)	417.3 (384.3, 470.3)	360.0 (328.0, 420.0)	<0.001
cIMT (mm)	0.46 (0.04)	0.47 (0.04)	—	0.570
Cardiac structure/function
LV mass (g)	96.2 (33)	87.5 (34)	84.5 (35)	0.212
LV mass index	31.1 (4.6)	31.2 (6.4)	33.2 (8.2)	0.191
LVED (cm)	4.43 (0.5)	4.29 (0.5)	4.20 (0.6)	0.097
LVED/BSA (cm/m²)	3.09 (0.6)	3.42 (0.6)	3.64 (0.8)	0.001
LVES (cm)	2.86 (0.4)	2.75 (0.4)	2.62 (0.4)	0.011
LVES/BSA (cm/m²)	2.00 (0.5)	2.18 (0.4)	2.28 (0.5)	0.010
Diastolic interventricular septum thickness (cm)	0.68 (0.1)	0.69 (0.2)	0.71 (0.1)	0.544
Diastolic posterior wall thickness (cm)	0.70 (0.1)	0.66 (0.1)	0.66 (0.1)	0.343
Systolic posterior wall thickness (cm)	1.11 (0.1)	1.06 (0.1)	1.08 (0.2)	0.580
Shortening fraction (%)	36.0 (3.6)	36.6 (3.5)	37.5 (4.0)	0.132
LV ejection fraction (%)	65.4 (5.3)	66.6 (4.5)	71.2 (6.3)	<0.001

Note. Data are presented as mean (SD) unless otherwise specified. Control, n = 82 for cardiac structure/function; SGA-naive, n = 36 for PWV; SGA-treated, n = 46 for PWV, n = 41 for cIMT. BSA = body surface area; cIMT = carotid intima-media thickness; LV = left ventricular; LVED = LV end-diastolic dimension; LVES = LV end-systolic dimension; PWV = pulse wave velocity; SGA = second-generation antipsychotic.

Table 4.

Relationships between SGA Treatment and Cardiac and Vascular Structure and Function.

Cardiovascular Parameter	SGA-treated vs. Control			SGA-naive vs. Control			SGA-treated vs. SGA-naive
Cardiovascular Parameter	B	95% CI	P	B	95% CI	P	B	95% CI	P
Model 1
PWV (geometric mean, %)	19.7	8.3 to 24.6	<0.001	16.2	12.7 to 28.4	<0.001	4.1	−3.9 to 11.6	0.354
cIMT (mm)	—			—			−0.005	−0.013 to 0.024	0.569
LVED/BSA (cm/m²)	−0.275	−0.418 to −0.131	<0.001	−0.224	−0.531 to 0.084	0.152	−0.325	−0.601 to −0.05	0.021
LVES/BSA (cm/m²)	−0.138	−0.234 to −0.041	0.006	−0.094	−0.292 to 0.104	0.348	−0.181	−0.386 to 0.023	0.081
Ejection fraction (%)	−5.84	−8.03 to −3.66	<0.001	−4.60	−6.91 to −2.29	<0.001	1.243	−1.074 to 3.56	0.289
Model 2
PWV (geometric mean, %)^a	11.1	3.95 to 18.8	0.002	12.9	5.60 to 20.6	<0.001	−1.54	−8.66 to 6.14	0.684
cIMT^b (mm)	—			—			−0.008	−0.030 to 0.013	0.441
LVED/BSA^c (cm/m²)	−0.159	−0.235 to −0.083	<0.001	−0.202	−0.353 to −0.050	0.010	−0.130	−0.311 to −0.051	0.156
LVES/BSA^c (cm/m²)	−0.067	−0.129 to −0.005	0.034	−0.081	−0.196 to 0.035	0.168	−0.061	−0.220 to 0.097	0.443
Ejection fraction^d (%)	−5.25	−7.85 to −2.65	<0.001	−4.13	−6.57 to −1.70	0.001	1.12	−1.68 to 3.92	0.430

Note. Model 1, unadjusted. Model 2, adjusted. BMI = body mass index; BSA = body surface area; cIMT = carotid intima-media thickness; LDL = low-density lipoprotein; LVED = Left ventricular end-diastolic dimension; LVES = Left ventricular end-systolic dimension; PWV = pulse wave velocity; SBP = systolic blood pressure; SGA = second-generation antipsychotic.

^a Models adjusted for age, sex, BMI, and SBP percentile.

^b Model adjusted for age sex, BMI, LDL cholesterol, and SBP percentile.

^c Models adjusted for age and sex.

^d Models adjusted for age, sex, BMI, SBP percentile, and heart rate.

LVED/BSA, LVES/BSA, and LV ejection fraction were lower in SGA-treated and SGA-naive children compared to control children (Table 3). The differences in LVED/BSA and LVES/BSA between control children and SGA-treated children remained after adjustments for sex and age (Table 4); only LVED/BSA remained significantly different between control and SGA-naive children after adjustments for sex and age. LV ejection fraction remained statistically significant after models were adjusted for age, sex, BMI, and systolic BP percentile (Table 4). No differences in LVED/BSA, LVES/BSA, or LV ejection fraction were observed between SGA-treated and SGA-naive children. No differences in LV mass indexed to height^2.7, diastolic interventricular septum thickness, or systolic or diastolic posterior wall thickness were observed among any of the groups (Table 3).

Discussion

The goal of this study was to assess whether treatment with SGAs is associated with cardiovascular dysfunction in children with mental health conditions in a cross-sectional population of children aged 6 to 18 years. We report that SGA-treated and SGA-naive children with mental illness have early indicators of cardiovascular dysfunction. We found that children with a mental health diagnosis have greater central PWV than children without a mental health diagnosis. Further, this relationship remained significant after adjustment for age, sex, BMI, and SBP, factors known to influence PWV. The greater PWV in these children was accompanied by lower LV ejection fraction and higher systolic LV dimension; however, these parameters were still in the physiologically healthy range.

There are no published data on the cardiovascular health of SGA-treated children despite the well-known cardiometabolic side effects that occur with SGA treatment.^{18

–25} We assessed PWV and cIMT, as noninvasive indicators of vascular health and atherosclerosis, that are strongly associated with future cardiovascular events in adults.^35,55 Only 2 studies have been published that investigated vascular function in SGA-treated adults.³⁸ Adults (n = 56) with schizophrenia or bipolar disorder treated with an SGA for a mean duration of 2 years had higher upper-limb PWV than age- and sex-matched control adults (n = 40) with no mental illness. Similarly, greater aortic PWV was reported in adults with schizophrenia (n = 10) who were treated with SGAs compared to healthy controls (n = 10).⁵⁶ However, these studies did not include subjects with mental illness who were SGA-naive and did not adjust for metabolic variables, such as BMI and BP, in the analyses. As such, it is difficult to interpret these studies because it is unknown whether the greater arterial stiffness is due to the SGA treatment or the mental illness.

We compared SGA-treated children and SGA-naive children with mental illness to distinguish the effects of mental illness from SGA treatment. Our finding that both SGA-treated and SGA-naive children have higher PWV than control children suggests that the underlying mental illness affected the vascular health of the children. However, our study is confounded by the fact that SGA-treated children likely have different psychiatric symptoms than untreated children and hence the indication for use of these medications. Larger longitudinal studies are required to definitely address the effects of SGA treatment on cardiovascular health in SGA-treated children.

Little is known about the cardiovascular health of children with mental illness. One cross-sectional study in adolescents (n = 364), mean age 14.7 years, found no association between self-reported negative mental health symptoms and mean arterial pressure, carotid-femoral PWV (using a SphygmoCor XCEL device), or cIMT.⁹ In contrast, another study reported that adolescents (n = 157) aged 16 to 21 years who experienced severe depressive symptoms had higher carotid-femoral PWV (by Doppler tracing) but had no differences in cIMT.¹⁰ The latter study parallels our findings that mental health conditions are associated with elevated PWV in youth. However, there are a few differences between these studies and our study that make comparisons difficult. We recruited subjects with diagnosed mental health disorders as per the DSM-IV-TR, whereas the studies by Lycett et al.⁹ and Dietz and Matthews¹⁰ determined the relationship between self-reported or self-assessed mental health symptoms and vascular health in adolescents without a diagnosed mental health condition. Several different techniques and locations can be used to assess PWV/arterial stiffness, further making comparisons between studies difficult. We used the well-established and reliable method of echocardiographic Doppler ultrasound traces from the thoracic aorta.⁵¹ This method is advantageous as it allows for assessment of aortic PWV and cardiac function/structure measurements simultaneously, whereas Lycett et al.⁹ and Dietz and Matthews¹⁰ analyzed carotid-femoral PWV. Further, it should be noted that another study reported no relationship between levels of psychosocial stress and depression and carotid-femoral PWV in children (n = 520) at baseline (mean age 11.6 years) and at follow-up 4 years later.⁵⁷

Childhood obesity is associated with altered cardiac morphology and function.³⁰ Several studies have reported greater LV dimensions and mass in children with obesity compared to children with a healthy BMI.^36,39,58 As such, we predicted that SGA-treated children may have altered cardiac morphology and function because of the metabolic complications. We observed no differences in LV mass, posterior wall thickness, or interventricular septum thickness among any of the children. However, we did find lower LVED/BSA, LVES/BSA, and LV ejection fraction in SGA-treated and SGA-naive children compared to control children. This suggests that the greater arterial stiffness in SGA-treated and SGA-naive children may be associated with increased afterload and early diastolic dysfunction resulting in a lower ejection fraction. There is little published data on the effects of antipsychotic medications on cardiac structure/function in children or adults. Only 1 recent small study reported that SGA-treated adults with schizophrenia (n = 14) had lower indexed LV mass but no differences in ejection fraction, determined by cardiac MRI, compared to untreated controls (n = 17).⁵⁹

SGA-treated and SGA-naive children also had lower DBP than control children. Arterial stiffness is an independent predictor of longitudinal changes in SBP and incident hypertension.^60,61 In the current study, we did not observe the effects of SGAs or mental illness on SBP but did observe lower DBP in SGA-treated and SGA-naive children compared to healthy controls. With greater arterial stiffness, the ability of vessels to cushion and accommodate blood flow during systole and then recoil during diastole is impaired. This may lead to higher SBP and lower DBP as previously reported in adults with metabolic syndrome.⁶² In our study, we observed no differences in SBP. However, it is possible that the elevations in PWV we observed in the SGA-treated and SGA-naive children may indicate early vascular structural changes that contribute to a lowering of DBP but precede alterations in SBP.

Limitations

This study must be interpreted within the context of its limitations. The cross-sectional design of this study limits our understanding of how SGA treatment may affect cardiovascular health over time in regard to changes in other cardiometabolic parameters, body composition, and other factors such as duration of SGA treatment. In our cohort, we observed a wide range of SGA treatment duration (from 3 to 96 months). Thus, it is difficult to accurately assess how SGAs may alter cardiovascular health over time. Further, we recognize that the majority of the children with mental illness were treated with other medications (e.g., antidepressants, psychostimulants) and that there is the possibility that these medications affect cardiovascular parameters. We also did not make use of research diagnostic interviews or scales to collect data on the severity of the mental health disorder or symptom severity, both of which could also affect cardiovascular health. We recognize that SGA-treated children likely had different psychiatric symptoms than SGA-naive children. However, these data were not collected and were unable to account for this in the current study. Family history of cardiovascular disease was not considered, and the children with mental illness may have a greater predisposition to cardiovascular disease than the control children. Additionally, because data for the control group were collected retrospectively, some data were unavailable for certain anthropometrics, cIMT, and circulating lipid concentrations. Therefore, we were unable to make comparisons between SGA-treated and SGA-naive subjects to age-and sex-matched control for these measures. Future prospective studies are warranted to further investigate how SGAs affect cardiovascular health in children and youth over time.

Conclusions

Overall, our findings provide evidence that SGA-treated and SGA-naive children with a mental health diagnosis have greater arterial stiffness than children without mental illness. The mechanisms underlying these effects are still unknown, and further investigations are pertinent for preventing long-term health complications. SGA treatment was not associated with alterations in cIMT, arterial stiffness, or cardiac structure/function in children. Long-term prospective studies are required to understand the pathology and progression of the cardiovascular dysfunction in children with mental illness. This will inform intervention trials designed to mitigate the cardiovascular dysfunction in these children and improve their long-term health outcomes.

Footnotes

Authors’ Note

Amanda M. Henderson analyzed the data and wrote the manuscript. Constadina Panagiotopoulos and Angela M. Devlin designed the research and supervised the study, wrote the manuscript, and had primary responsibility for final content of the manuscript. Nazrul Islam analyzed the data and critically revised the manuscript. George G. S. Sandor provided expertise on cardiovascular assessments and interpretation of data and critically revised the manuscript. All authors approved the final manuscript as submitted and agreed to be accountable for all aspects of the work.

Acknowledgment

The authors thank Lindsey Williams for assistance with echocardiography and Astrid De Souza for assistance with data from control subjects.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by funding from the British Columbia Mental Health and Substance Use Services (to Angela M Devlin and Constadina Panagiotopoulos). Angela M Devlin is supported by an Investigator Grant from the BC Children’s Hospital Research Institute.

ORCID iD

Angela M. Devlin, PhD

References

Mental Health Commission. Making the case for investing in mental health in Canada. London (ON): Mental Health Commission; 2013.

Merikangas

Burstein

, et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication–Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry. 2010;49(10):980–989.

Hennekens

Hollar

Casey

. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150(6):1115–1121.

Gale Catharine

Batty

Osborn David

Tynelius

Rasmussen

. Mental disorders across the adult life course and future coronary heart disease. Circulation. 2014;129(2):186–193.

Osborn

DPJ

Levy

Nazareth

Petersen

Islam

King

. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom’s General Practice Research Database. JAMA Psychiatry. 2007;64(2):242–249.

Raitakari

Juonala

Kähönen

, et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood. JAMA. 2003;290(17):2277–2283.

Juonala

Järvisalo

Mäki-Torkko

Kähönen

Viikari

JSA

Raitakari

. Risk factors identified in childhood and decreased carotid artery elasticity in adulthood. Circulation. 2005;112(10):1486–1493.

Goldstein

Carnethon

Matthews

, et al. Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease. Circulation. 2015;132(10):965–986.

Lycett

McNamara

Mensah

, et al. Associations of mental health with cardiovascular risk phenotypes and adiposity in adolescence: a cross-sectional community-based study. J Paediatr Child Health. 2018;54(6):677–684.

10.

Dietz

Matthews

. Depressive symptoms and subclinical markers of cardiovascular disease in adolescents. J Adolesc Health. 2011;48(6):579–584.

11.

Osika

Montgomery

Dangardt

, et al. Anger, depression and anxiety associated with endothelial function in childhood and adolescence. Arch Dis Child. 2011;96(1):38–43.

12.

Tomfohr

Murphy

MLM

Miller

Puterman

. Multiwave associations between depressive symptoms and endothelial function in adolescent and young adult females. Psychosom Med. 2011;73(6):456–461.

13.

De Hert

Detraux

van Winkel

Correll

. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8(2):114–126.

14.

Lin

Chen

Tsang

, et al. Association between antipsychotic use and risk of acute myocardial infarction. Circulation. 2014;130(3):235–243.

15.

Di Pietro

Illes

. Rising antipsychotic prescriptions for children and youth: cross-sectoral solutions for a multimodal problem. CMAJ. 2014;186(9):653–654.

16.

Sohn

Moga

Blumenschein

Talbert

. National trends in off-label use of atypical antipsychotics in children and adolescents in the United States. Medicine. 2016;95(23):e3784.

17.

Ronsley

Scott

Warburton

, et al. A population-based study of antipsychotic prescription trends in children and adolescents in British Columbia from 1996 to 2011. Can J Psychiatry. 2013;58(6):361–369.

18.

Panagiotopoulos

Ronsley

Davidson

. Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications. Can J Psychiatry. 2009;54(11):743–749.

19.

Devlin

Ngai

Ronsley

Panagiotopoulos

. Cardiometabolic risk and the MTHFR C677T variant in children treated with second-generation antipsychotics. Transl Psychiatry. 2012;2(1):e71.

20.

Panagiotopoulos

Ronsley

Kuzeljevic

Davidson

. Waist circumference is a sensitive screening tool for assessment of metabolic syndrome risk in children treated with second-generation antipsychotics. Can J Psychiatry. 2012;57(1):34–44.

21.

Ronsley

Nguyen

Davidson

Panagiotopoulos

. Increased risk of obesity and metabolic dysregulation following 12 months of second-generation antipsychotic treatment in children: a prospective cohort study. Can J Psychiatry. 2015;60(10):441–450.

22.

Barker

Sable

Montgomery

, et al. Diet and cardiometabolic side effects in children treated with second-generation antipsychotics. Clin Nutr ESPEN. 2018;23:205–211.

23.

Correll

Manu

Olshanskiy

Napolitano

Kane

Malhotra

. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765–1773.

24.

Arango

Giráldez

Merchán-Naranjo

, et al. Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients. J Am Acad Child Adolesc Psychiatry. 2014;53(11):1179–1190.

25.

Ilies

Huet

A-S

Lacourse

Roy

Stip

Amor

. Long-term metabolic effects in French-Canadian children and adolescents treated with second-generation antipsychotics in monotherapy or polytherapy: a 24-month descriptive retrospective study. Can J Psychiatry. 2017;62(12):827–836.

26.

Kryzhanovskaya

Millen

Acharya

Jen

Osuntokun

. Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine. J Child Adolesc Psychopharmacol. 2012;22(2):157–165.

27.

Safer

. A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol. 2004;24(4):429–436.

28.

Galling

Roldán

Nielsen

, et al. Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis. JAMA Psychiatry. 2016;73(3):247–259.

29.

Rajkumar

Horsdal

Wimberley

, et al. Endogenous and antipsychotic-related risks for diabetes mellitus in young people with schizophrenia: a Danish population-based cohort study. Am J Psychiatry. 2017;174(7):686–694.

30.

Cote

Harris

Panagiotopoulos

Sandor

GGS

Devlin

. Childhood obesity and cardiovascular dysfunction. J Am Coll Cardiol. 2013;62(15):1309–1319.

31.

Iannuzzi

Licenziati

Acampora

, et al. Increased carotid intima-media thickness and stiffness in obese children. Diabetes Care. 2004;27(10):2506–2508.

32.

Koopman

McCrindle

Slorach

, et al. Interaction between myocardial and vascular changes in obese children: a pilot study. J Am Soc Echocardiogr. 2012;25(4):401–410.

33.

Lorenz

Markus

Bots

Rosvall

Sitzer

. Prediction of clinical cardiovascular events with carotid intima-media thickness. Circulation. 2007;116(9):459–467.

34.

Cote

Phillips

Harris

Sandor

Panagiotopoulos

Devlin

. Obesity and arterial stiffness in children: systematic review and meta-analysis. Arterioscler Thromb Vasc Biol. 2015;35(4):1038–1044.

35.

Cavalcante

Lima

JAC

Redheuil

Al-Mallah

. Aortic stiffness current understanding and future directions. J Am Coll Cardiol 2011;57(14):1511–1522.

36.

de Jonge Layla

van Osch-Gevers

Willemsen

, et al. Growth, obesity, and cardiac structures in early childhood: the Generation R Study. Hypertension. 2011;57(5):934–940.

37.

de Ferranti Sarah

Steinberger

Ameduri

, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American heart association. Circulation. 2019;139(13):e603–e634.

38.

Fındıklı

Gökçe

Nacitarhan

, et al. Arterial stiffness in patients taking second-generation antipsychotics. Clin Psychopharmacol Neurosci. 2016;14(4):365–370.

39.

Harris

Al Saloos

De Souza

, et al. Biophysical properties of the aorta and left ventricle and exercise capacity in obese children. Am J Cardiol. 2012;110(6):897–901.

40.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington (DC): American Psychiatric Association; 2000.

41.

Marshall

Tanner

. Variations in pattern of pubertal changes in girls. Arch Dis Childhood. 1969;44(235):291–303.

42.

Marshall

Tanner

. Variations in pattern of pubertal changes in boys. Arch Dis Childhood. 1970;45(239):13–23.

43.

Kuczmanski

Ogden

Grummer-Strawn

, et al. CDC growth charts: United States. Adv Data. 2000;8(314):1–27.

44.

Sharma

Metzger

Daymont

Hadjiyannakis

Rodd

. LMS tables for waist-circumference and waist-height ratio z-scores in children aged 5-19 y in NHANES III: association with cardio-metabolic risks. Pediatr Res. 2015;78(6):723–729.

45.

Flynn

Kaelber

Baker-Smith

, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017;140(3):e20171904.

46.

Levy

Matthews

Hermans

. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998;21(12):2191–2192.

47.

Lopez

Colan

Frommelt

, et al. Recommendations for quantification methods during the performance of a pediatric echocardiogram: a report from the Pediatric Measurements Writing Group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council. J Am Soc Echocardiogr. 2010;23(5):465–495.

48.

Haycock

Schwartz

Wisotsky

. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J Pediatr. 1978;93(1):62–66.

49.

Devereux

Reichek

Echocardiographic determination of left ventricular mass in man Anatomic validation of the method. Circulation. 1977;55(4):613–618.

50.

Chinali

Emma

Esposito

, et al. Left ventricular mass indexing in infants, children, and adolescents: a simplified approach for the identification of left ventricular hypertrophy in clinical practice. J Pediatr. 2016;170:193–198.

51.

Sandor

GGS

Hishitani

Petty

, et al. A novel Doppler echocardiographic method of measuring the biophysical properties of the aorta in pediatric patients. J Am Soc Echocardiogr. 2003;16(7):745–750.

52.

Bradley

Potts

DeSouza

Sandor

GGS

. Echocardiographic Doppler assessment of the biophysical properties of the aorta in pediatric patients with the Marfan syndrome. Am J Cardiol. 2005;96(9):1317–1321.

53.

Aminbakhsh

Frohlich

Mancini

. Detection of early atherosclerosis with B mode carotid ultrasonography: assessment of new quantitative approach. Clin Invest Med. 1999;22(6):265–274.

54.

Vandenbroucke

von Elm

Altman

, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLOS Med. 2007;4(10): e297.

55.

Mattace-Raso

FUS

van der Cammen

TJM

Hofman

, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation. 2006;113(5):657–663.

56.

Phillips

Warburton

DER

Flynn

Fredrikson

Lang

. Assessment of arterial stiffness among schizophrenia-spectrum disorders using aortic pulse wave velocity and arterial compliance: a pilot study. Psychiatry Res. 2014;215(1):14–19.

57.

Olive

Abhayaratna

Byrne

Telford

Berk

Telford

. Depression, stress and vascular function from childhood to adolescence: a longitudinal investigation. Gen Hosp Psychiatry. 2020;62:6–12.

58.

Mehta

Richards

Lorber

Rosenthal

. Abdominal obesity, waist circumference, body mass index, and echocardiographic measures in children and adolescents. Congenit Heart Dis. 2009;4(5):338–347.

59.

Pillinger

Osimo

de Marvao

, et al. Cardiac structure and function in patients with schizophrenia taking antipsychotic drugs: an MRI study. Transl Psychiatry. 2019;9(1):163.

60.

Laurent

Boutouyrie

Asmar

, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37(5):1236–1241.

61.

Najjar

Scuteri

Shetty

, et al. Pulse wave velocity is an independent predictor of the longitudinal increase in systolic blood pressure and of incident hypertension in the Baltimore Longitudinal Study of Aging. J Am Coll Cardiol. 2008;51(4):1377–1387.

62.

Safar

Balkau

Lange

, et al. Hypertension and vascular dynamics in men and women with metabolic syndrome. J Am Coll Cardiol. 2013;61(1):12.

Greater Arterial Stiffness in Children with or without Second-generation Antipsychotic Treatment for Mental Health Disorders: Rigidité Artérielle Plus Importante Chez Les Enfants Avec ou Sans Traitement Par Antipsychotiques de la Deuxième Génération Pour des Troubles de Santé Mentale

Abstract

Objective:

Methods:

Results:

Conclusions:

Keywords

Introduction

Materials and Methods

Study Design and Subject Recruitment

Anthropometric, Clinical, and Biochemical Analyses

Echocardiography and Vascular Measurements

Statistical Analyses

Results

Discussion

Limitations

Conclusions

Footnotes

Authors’ Note

Acknowledgment

Declaration of Conflicting Interests

Funding

ORCID iD

References